Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Twist1 in podocytes ameliorates podocyte injury and proteinuria by limiting CCL2-dependent macrophage infiltration
Jiafa Ren, … , Robert F. Spurney, Steven D. Crowley
Jiafa Ren, … , Robert F. Spurney, Steven D. Crowley
Published August 9, 2021
Citation Information: JCI Insight. 2021;6(15):e148109. https://doi.org/10.1172/jci.insight.148109.
View: Text | PDF
Research Article Nephrology

Twist1 in podocytes ameliorates podocyte injury and proteinuria by limiting CCL2-dependent macrophage infiltration

  • Text
  • PDF
Abstract

The transcription factor Twist1 regulates several processes that could impact kidney disease progression, including epithelial cell differentiation and inflammatory cytokine induction. Podocytes are specialized epithelia that exhibit features of immune cells and could therefore mediate unique effects of Twist1 on glomerular disease. To study Twist1 functions in podocytes during proteinuric kidney disease, we employed a conditional mutant mouse in which Twist1 was selectively ablated in podocytes (Twist1-PKO). Deletion of Twist1 in podocytes augmented proteinuria, podocyte injury, and foot process effacement in glomerular injury models. Twist1 in podocytes constrained renal accumulation of monocytes/macrophages and glomerular expression of CCL2 and the macrophage cytokine TNF-α after injury. Deletion of TNF-α selectively from podocytes had no impact on the progression of proteinuric nephropathy. By contrast, the inhibition of CCL2 abrogated the exaggeration in proteinuria and podocyte injury accruing from podocyte Twist1 deletion. Collectively, Twist1 in podocytes mitigated urine albumin excretion and podocyte injury in proteinuric kidney diseases by limiting CCL2 induction that drove monocyte/macrophage infiltration into injured glomeruli. Myeloid cells, rather than podocytes, further promoted podocyte injury and glomerular disease by secreting TNF-α. These data highlight the capacity of Twist1 in the podocyte to mitigate glomerular injury by curtailing the local myeloid immune response.

Authors

Jiafa Ren, Yuemei Xu, Xiaohan Lu, Liming Wang, Shintaro Ide, Gentzon Hall, Tomokazu Souma, Jamie R. Privratsky, Robert F. Spurney, Steven D. Crowley

×

Figure 7

Twist1 in podocytes suppresses macrophage accumulation in glomeruli and renal interstitium after NTS injury.

Options: View larger image (or click on image) Download as PowerPoint
Twist1 in podocytes suppresses macrophage accumulation in glomeruli and ...
(A) Representative flow plots of CD11b+CCR2+ macrophages from kidneys of NTS-treated WT and Twist1-PKO animals. (B) Absolute numbers of CD11b+CCR2+ macrophages per gram of WT or Twist1-PKO kidney (n = 7, t test). (C) Representative flow plots of CD11b+Ly6Chi-infiltrating monocytes from kidneys of NTS-treated WT and Twist1-PKO animals. (D) Absolute numbers of CD11b+Ly6Chi-infiltrating monocytes per gram of WT and Twist1-PKO kidney (n = 7, t test). (E) Representative sections of CD64-stained glomeruli from NTS-treated WT and Twist1-PKO animals. Scale bar: 40 μm. (F) Quantitative determination of glomerular CD64-positive cells in NTS-treated WT and Twist1-PKO cohorts (n = 7, t test). (G) Representative CD64-stained kidney sections from NTS-treated WT and Twist1-PKO mice. Scale bar: 100 μm. (H) Quantitative determination of kidney interstitial CD64-positive cells in NTS-treated WT and Twist1-PKO cohorts (n = 7, t test). All t tests were 2 tailed. *P < 0.05. NTS, nephrotoxic serum; Twist1-PKO, Pod-Cre Twist1fl/fl.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts